Medpace Holdings (MEX:MEDP) ROCE %: 81.99% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:MEDP Medpace Holdings Inc MEX:MEDP
93 GF Score
Price MXN7,022.03
GF Value MXN6,131.53
! 2 Warning Signs
View Full Analysis

What is Medpace Holdings ROCE %?

Medpace Holdings MEX:MEDP 93 ROCE % is 81.99% as of Jun. 2026. GuruFocus rates MEX:MEDP with a GF Score™ of 93/100 and a GF Value™ of MXN6,131.53. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medpace Holdings's annualized ROCE % for the quarter that ended in Jun. 2026 was 81.99%.

Medpace Holdings  (MEX:MEDP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medpace Holdings ROCE % Related Terms

Medpace Holdings ROCE % Historical Data

* Premium members only.

The historical data trend for Medpace Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medpace Holdings ROCE % Chart

Medpace Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.62 32.61 49.45 56.15 59.91

Medpace Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 84.69 136.75 110.50 79.98 81.99
MEX:MEDP
93GF Score
Medpace Holdings Inc MEX:MEDP
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medpace Holdings ROCE % Calculation

Medpace Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=9631.879/( ( (43815.031 - 23036.226) + (35569.756 - 24195.123) )/ 2 )
=9631.879/( (20778.805+11374.633)/ 2 )
=9631.879/16076.719
=59.91 %

Medpace Holdings's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=10247.728/( ( (38402.672 - 24254.234) + (35895.751 - 25046.801) )/ 2 )
=10247.728/( ( 14148.438 + 10848.95 )/ 2 )
=10247.728/12498.694
=81.99 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 81.99% mean?
Medpace Holdings (MEX:MEDP) has a ROCE % of 81.99% as of Jun. 2026.
Is Medpace Holdings' ROCE % too high?
Medpace Holdings' current ROCE % is 81.99%. Overall, Medpace Holdings has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' ROCE % compare to ICLR and RVTY?
Medpace Holdings' ROCE % of 81.99% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Medpace Holdings's current ROCE % is 81.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Medpace Holdings (MEX:MEDP) has a current ROCE % of 81.99%. The stock's GF Value™ is MXN6,131.53, compared to a current price of MXN7,022.03 — trading 14.5% above its estimated fair value. The current ROCE % is 81.99%. Medpace Holdings' overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Medpace Holdings (MEX:MEDP), the current ROCE % is 81.99% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medpace Holdings (MEX:MEDP) Overvalued in 2026?

Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued. The current stock price of MXN7,022.03 is trading 14.5% above its estimated GF Value™ of MXN6,131.53.

Key valuation signals for MEX:MEDP:

  • ROCE %: 81.99%
  • GF Value™: MXN6,131.53 vs. price of MXN7,022.03 (14.5% above fair value)
  • GF Score™: 93/100 with 2 warning signs

No single metric tells the full story. See the MEX:MEDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medpace Holdings Business Description

Other Exchanges MEDP:USA01P:Germany
Address 5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
93GF Score

Get the complete analysis for MEX:MEDP

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN7,022.03
Price
MXN6,131.53
GF Value